Get the Stockscreener App
0.8019
11.86%
-0.1079
After Hours:
.79
-0.0119
-1.48%
Cyclo Therapeutics Inc stock is traded at $0.8019, with a volume of 99,447.
It is down -11.86% in the last 24 hours and down -2.33% over the past month.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
See More
Previous Close:
$0.9098
Open:
$0.89
24h Volume:
99,447
Relative Volume:
0.07
Market Cap:
$26.25M
Revenue:
$1.13M
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.9113
EPS:
-0.88
Net Cash Flow:
$-18.37M
1W Performance:
-17.80%
1M Performance:
-2.33%
6M Performance:
+2.81%
1Y Performance:
-54.18%
1-Day Range:
$0.8019
$0.9098
1-Week Range:
$0.8019
$0.9994
52-Week Range:
$0.55
$1.79
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Name
Cyclo Therapeutics Inc
Sector
Phone
386-418-8060
Address
6714 NW 16TH STREET, SUITE B, GAINESVILLE
Compare CYTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTH
Cyclo Therapeutics Inc
|
0.8019 | 26.25M | 1.13M | -20.74M | -18.37M | -0.88 |
|
ZTS
Zoetis Inc
|
165.31 | 74.02B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.15 | 45.90B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.08 | 44.64B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.23B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.57 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Cyclo Therapeutics Inc Stock (CYTH) Latest News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders - The Malaysian Reserve
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc.CYTH - Business Wire
Cyclo Therapeutics extends merger agreement with Rafael Holdings - MSN
Reviewing Cyclo Therapeutics (NASDAQ:CYTH) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
Cyclo Therapeutics Inc (CYTH) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Adversity is less terrifying than hope: Cyclo Therapeutics Inc (CYTH) - SETE News
Rafael Holdings Extends Merger Agreement Deadline By Investing.com - Investing.com Australia
Rafael Holdings Extends Merger Agreement Deadline - MSN
Cyclo Therapeutics logs efficacy win in pivotal Niemann-Pick disease trial - Clinical Trials Arena
Conduit, MGO Global, and Cyclo Therapeutics: Penny Stocks to Watch This Week - PUNE.NEWS
3 Penny Stocks to Watch Now, 2/11/25 - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Will Cyclo Therapeutics Inc (CYTH) meet earnings estimates this quarter? - US Post News
Investing in Rigetti Computing Inc (RGTI) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Cyclo Therapeutics reports promising NPC1 treatment findings - MSN
Clinical Trials News Live Feed - StockTitan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYTH, VGR, TTNP on Behalf of Shareholders - ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Cyclo Therapeutics Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Is Lipella Pharmaceuticals Inc (NASDAQ:LIPO) stock a better investment at this time? - US Post News
What will the future hold for Apple Inc (NASDAQ:AAPL) stock? - US Post News
Cyclo Therapeutics Inc (NASDAQ:CYTH) stock: You might be surprised - US Post News
Cyclo Therapeutics Presents Positive Data From Phase 3 NPC1 Sub-Study - Nasdaq
Artificial Intelligence (AI) News Live Feed - StockTitan
SolarWinds Corp (SWI) Stock Price and Analyst Predictions - The News Heater
Analyzing the Price-to-Earnings Ratio of Cyclo Therapeutics Inc (CYTH) - The News Heater
Stock market today: Garden Stage skyrocketed by 126.15% while Nikola Corporation plunged by 40.19% in early trading - Business Upturn
FNB’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Cyclo Therapeutics reports promising NPC1 treatment findings By Investing.com - Investing.com South Africa
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC(TM) Open-Label Sub-Study in Patients ( - Marketscreener.com
Breakthrough NPC1 Treatment Data: 87% of Young Patients Show Recovery Signs in Cyclo Trial - StockTitan
Juniper Networks Inc (JNPR) presents a great opportunity, but the stock is slightly undervalued - US Post News
Denny’s Corp (DENN) Stock Faces 4.27% Weekly Volatility - The News Heater
OceanFirst Financial Corp (OCFC) vs. Its Peers: A Comparison - The News Heater
Cyclo Therapeutics extends merger agreement with Rafael Holdings By Investing.com - Investing.com South Africa
Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) versus Cyclo Therapeutics (NASDAQ:CYTH) Head-To-Head Contrast - Defense World
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates WMPN, ALVR, CYTH on Behalf of Shareholders - Finansavisen
AMRN Stock Drops Amid Market Volatility - GuruFocus.com
Cyclo Therapeutics (CYTH) Stock Price, News & Analysis - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerCYTH, ALVR, WMPN, OMC - The Malaysian Reserve
Cyclo Therapeutics Faces Potential Delisting Due to Failure to Hold Annual Shareholders MeetingUNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. – January 10, 2025 – ON January 10, 2025, Cyclo Therapeutics, Inc. (the “C - Defense World
Rafael Holdings reports favorable shareholder votes - Investing.com India
Cyclo Therapeutics to Present Groundbreaking Trappsol® Cyclo™ Research at WORLDSymposium 2025 - StockTitan
Cyclo Therapeutics faces Nasdaq delisting over meeting lapse - Investing.com
Cyclo Therapeutics Inc Stock (CYTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.92%
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):